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Abstract Matrix metalloproteinases (MMPs) have been
implicated to play an important role in the destruction of
the extracellular matrix in diseases of the central nervous
system. This study investigated whether the expression of
one of these proteases, MMP-9 in blood, is related to the
size of human brain infarcts assessed with magnetic reso-
nance imaging. Consecutively, twenty-one acute stroke
patients were included prospectively into our study. In
blood samples drawn within 24 h after onset, MMP-9
RNA-expression and proteolytic-activity were analyzed
by quantitative polymerase chain reaction and gelatin
zymography, respectively. The ischemic lesion volumes in
time to peak perfusion maps and diffusion weighted
imaging were measured morphometrically. RNA-expres-
sion levels of MMP-9 in peripheral blood mononuclear
cells (PBMCs) correlated with the brain infarct lesion
(TTP-delay 4 s, r = -0.61, p = 0.007; TTP-delay 6 s:
r = -0.58, p = 0.012; DWI r = -0.47; p = 0.047). Our
preliminary results demonstrate that MMP-9 RNA is
upregulated in PBMCs in proportion to ischemia. These
findings suggest that MMP-9 might contribute to the
manifestation of ischemic brain damage. Since MMP-9 is
upregulated in acute ischemia inhibition of MMP-9 may
represent a complementary treatment target in acute stroke
therapy.
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Introduction
Brain ischemia activates a complex cascade of events
including glutamate release, leukocyte infiltration and
breakdown of the blood–brain barrier leading to vasogenic
edema [1]. In experimental stroke models it was found that
matrix metalloproteinases (MMPs) are involved in the
destruction of the basal lamina and the extracellular matrix
[1]. Furthermore, inhibition of matrix metalloproteinase-9
expression was found in experimental stroke models to
reduce infarct size [2, 3]. A particular role is the closure of
the blood–brain barrier by matrix metalloproteinase inhi-
bition which reduces rtPA-mediated mortality in cerebral
ischemia with delayed reperfusion [4, 5].
In this present study, we explored the expression of
MMP-9 in relation to the volume of ischemia as assessed in
perfusion imaging and the volume of the infarct lesion as
assessed in diffusion weighted imaging (DWI) in acute
stroke patients. In previous magnetic resonance imaging
(MRI) studies we have shown that abnormalities in time-
to-peak (TTP) maps of brain perfusion and in DWI in acute
stroke provide reliable means to assess the volume of
ischemic brain damage in acute stroke [6, 7].
In this study, we used the volume of ischemia as found
in TTP maps and the volume of ischemic tissue damage as
found in DWI maps related to the expression of MMP-9
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measured with quantitative polymerase chain reaction and
gelatin zymography in peripheral blood.
Materials and methods
Study population and clinical protocol
Consecutively, twenty-one acute stroke patients aged
62.7 ± 14.3 years, 11 males and 10 females were included
into the study. They were moderately affected as assessed
with the NIH stroke scale, 6.3 ± 5.2 points, and received
multimodal MRI within 4.6 ± 1.9 h after stroke onset. All
patients received complete stroke-imaging including mag-
netic resonance imaging (MRI), diffusion weighted imag-
ing (DWI), perfusion weighted imaging (PWI), and
magnetic resonance angiography (MRA). Eight patients
reached the hospital within 6 h to qualify for systemic
thrombolysis therapy, three did not reach the hospital in
time, and the other 10 did not required thrombolysis ther-
apy. All patient characteristics can be revised in Tables 1
and 2. Venous blood samples were taken 17.5 ± 5.7 h
after stroke onset. All patients gave informed consent.
MRI protocol
The MRI was performed with a 1.5-T whole-body imaging
system (Siemens Magnetom Vision, Siemens Medical
Systems, Germany). TTP parametric maps and DWI
maps were calculated using in-house written software
STROKETOOL.
Lesion volumetry on perfusion/diffusion-weighted MR
images
The abnormalities of TTP and DWI were measured using
volumetric analysis in relation to reference of the con-
tralateral non-affected hemisphere in each patient as
described previously [7]. We used a time delay of 6 s
after bolus arrival relative to the unaffected contrale-
sional hemisphere to assess the subsequent infarct lesion
[6, 7]. A TTP delay of 4 s estimated the critically
ischemic brain tissue that could be salvaged by early
reperfusion [6, 7]. A threshold of 20 percent relative to
the non-affected hemisphere was used for assessing the
DWI lesion [6, 7].
MMP-9 zymography and quantitative PCR
Proteolytic activity of MMP-9 in peripheral blood mono-
nuclear cells (PBMCs) was assayed by gelatin zymography
[8]. To study MMP-9 mRNA-expression we used a semi-
quantitative PCR (qPCR) and applied the SYBR Green
Method (SYBR Green Master Mix, Applied Biosystems,
Darmstadt, Germany).
Statistical analysis
Statistical analyses were performed with SPSS for
windows, Version 15.0 (SPSS inc., Chicago, USA). P val-
ues \0.05 were considered statistically significant.
Table 1 Summary of data of the study population
Patient no. Age/sex Baseline
NIHSS
Blood sampling
after onset (h)
Thrombolysis
(Y/N)
1. (P.H.) 71/M 4 22 N
2. (G.G.) 64/M 10 21 Y
3. (A.M.) 65/M 4 23 N
4. (R.K.) 61/F 2 11 N
5. (V.R) 62/F 4 16 N
6. (H.T.) 34/F 2 8 Y
7. (H.W.) 64/M 10 11 N
8. (F.A.) 69/F 10 20 Y
9. (W.W.) 57/M 2 14 N
10. (S.M.) 85/F 11 9 Y
11. (M.A.) 78/F 3 23 N
12. (R.W.) 79/M 4 22 Y
13. (K.M) 73/F 13 23 N
14. (O¨.P.) 63/F 3 18 N
15. (B.V.) 43/F 0 23 N
16. (S.R.) 41/F 4 22 N
17. (W.K.) 58/M 4 9 Y
18. (W.J.) 58/F 16 20 Y
19. (K.H.) 69/M 11 21 Y
20. (L.I.) 62/F 8 18 N
21. (P.B.) 36/F 3 22 N
M male, F female, NIHSS National Institutes of Health Stroke Scale,
Y yes, N no, h hours
Table 2 Characteristics of the study population
Age, years (SD) 62.7 ± 14.3
Sex (M), No. (%) 11 (52.4)
Hypertension, No (%) 14 (66.6)
Smoker, No. (%) 14 (66.7)
Diabetics, No. (%) 5 (23.8)
Hypercholesterolemia, No. (%) 8 (42.8)
Coronary disease, No. (%) 5 (23.8)
Previous strokes, No. (%) 9 (42.9)
NIHSS, points (SD) 6.3 ± 5.2
y years, SD standard deviation, M male, NIHSS National Institutes of
Health Stroke Scale
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Results
The perfusion lesion volumes with a TTP-delay of 4 s were
on average 33.3 ± 56.6 and 22.6 ± 40.7 ml for a TTP-
delay of 6 s. Both lesion volumes correlated with the
MMP-9 mRNA expression in PBMCs as assessed with the
DCt-value (TTP-delay 4 s, r = -0.61; p = 0.007; TTP
6 s, r = -0.58; p = 0.012). DCt resulting from subtracting
the measured Ct value of the housekeeping gene (18S),
from the measured Ct value of the target gene (MMP9). As
a result, the smaller the delta Ct value, the higher the
expression of the target gene. This is illustrated in Fig. 1.
The DWI lesion volumes were on average 7.6 ± 15.4 ml
showing a slight correlation with the DCt-value of mRNA
expression (Fig. 1c, r = -0.47; p = 0.047). There was no
correlation of the lesion volumes with the proteolytic
MMP-9 activity in PBMCs as assessed with zymography.
There was no significant differences between thrombolysed
patients and not-thrombolysed patients either in the MMP-
9 mRNA expression (p = 0.766) or in the proteolytic
MMP-9 activity (p = 0.111).
Discussion
Our preliminary findings have shown that MMP-9 RNA-
expression in PBMCs correlated significantly with the
lesion volume in acute cerebral stroke as assessed by MRI.
Specifically, our findings show that the perfusion deficit
correlated with MMP-9 expression in qPCR and this cor-
relation was stronger than that with the DWI changes.
These data support previous findings that revealed high
MMP-9 levels in peripheral blood samples after ischemic
stroke in humans indicating poor neurological outcome and
hemorrhagic transformation after thrombolytic therapy [5].
Still, it is difficult to suggest that the MMP-9 RNA may
represent a good biomarker for the severity of acute brain
ischemia since our study is exploratory and we do not
present any data on sensitivity or specificity.
Cerebral ischemia can be assessed non-invasively even
within minutes after stroke onset using perfusion MRI. In
acute stroke the perfusion deficit can be determined using
time-to-peak (TTP) maps, which show the delay of the
arrival of gadolinium in the brain after intravenous appli-
cation as compared with the contralesional non-affected
cerebral hemisphere [6, 7]. The tissue volume with a TTP-
delay of 4 s was shown to have the highest correlation with
the neurological deficit, while the tissue volume with a
TTP-delay of 6-s images signifies the remaining infarct
lesion [6, 7]. In fact, in early MRI within 3 h after stroke
onset DWI lesions were not fully developed [7]. Thus, our
findings suggest that the RNA-expression of MMP-9 sig-
nified the severity of ischemia rather than the manifest
infarct volume. This was surprising, since the blood sam-
ples were taken only hours after stroke onset (\24 h)
contradicting an early immunological reaction in the acute
phase of stroke. Also, PBMCs represent 60–75% of all
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Fig. 1 Relation of MRI lesion volumes and MMP-9 expres-
sion. a Relation of TTP-delay 4 s and DCt (r = -0.61; p = 0.007).
b Relation of TTP-delay 6 s and DCt (r = -0.58; p = 0.012).
c Relation of DWI and DCt (r = -0.47; p = 0.047)
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circulating leukocytes and are known to account for the
majority of fast MMP-9 pro-enzyme release into blood [9].
In fact, animal studies have shown that the expression of
MMP-9 is responsible for the extent of the brain infarct [3,
10]. It is possible that this discrepancy was due to eight
patients treated successfully with systemic thrombolysis in
our group. But this may also reflect that proteolytic activity
of MMP-9 in zymography did not show a relation with the
lesions volumes. Nevertheless, as thrombolytic therapy was
reported to activate MMP-9, complementary therapy by
antagonizing MMP-9 may be beneficial in acute stroke
patients [2, 11–13]. In fact, specific antagonists have been
applied to inhibit the expression of MMP-9 and found to
counteract the development of the infarct in a stroke model
[4]. Thus, we would like to speculate that inhibition of
MMP-9 might be a promising additional approach for
salvaging brain tissue threatened by acute severe ischemia.
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